CVS Health price target raised to $80 from $68 at Morgan Stanley

Morgan Stanley raised the firm’s price target on CVS Health (CVS) to $80 from $68 and keeps an Overweight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.